After 2 failed antidepressants, raise TMS and esketamine
In community interventional psychiatry practices, the typical referral looks the same week after week. The patient is in the fifth or sixth year of a major depressive episode and c...
In community interventional psychiatry practices, the typical referral looks the same week after week. The patient is in the fifth or sixth year of a major depressive episode and c...
For most of the past two decades, community practice has managed treatment-resistant depression (TRD) the way STAR*D described: one medication after another, with remission rates f...
Depression treatment doesn’t always produce the improvements people expect, even after months of medication, therapy or lifestyle changes. Some individuals experience only partial...
—Northwest organic apple growers have been finding pockets of resistance to some strains of codling moth granulosis virus, but researchers and experts are exploring other reasons w...
A comprehensive review finds that AML cells commonly overcome epigenetic drugs through compensatory chromatin and transcriptional adaptation, favoring biomarker-selected combinatio...
Most of us know the moment. A patient has failed two, sometimes three, adequate antidepressant trials, maybe an augmentation agent too. They are still depressed, often demoralized,...
The development of treatment resistance is one of the key challenges in modern cancer and antibiotic therapy. New therapeutic approaches aim to curb the spread of resistance throug...
Chemotherapy has long been a workhorse against metastatic breast cancer, yet for most patients with estrogen receptor-positive (ER+) disease, the cancer eventually wins the evoluti...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.